and Co-infection in a Patient with Giant-cell Arteritis.

Felisbela Gomes, Pedro La Feria, Catarina Costa, Helena Texeira
Author Information
  1. Felisbela Gomes: Unidade Funcional de Medicina 2.1, Hospital de Santo António dos Capuchos, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.
  2. Pedro La Feria: Unidade Funcional de Medicina 2.1, Hospital de Santo António dos Capuchos, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.
  3. Catarina Costa: Unidade Funcional de Medicina 2.1, Hospital de Santo António dos Capuchos, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.
  4. Helena Texeira: Unidade Funcional de Medicina 2.1, Hospital de Santo António dos Capuchos, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.

Abstract

Immunosuppressed patients are at greater risk of unusual infections. The authors present the case of a woman with giant-cell arteritis, on oral steroids, who developed cavitating pneumonia due to co-infection with and . Reports of such co-infection are rare in the literature. This case highlights the importance of considering rare pathogens in immunosuppressed patients who present with non-specific symptoms, as well as the impact of such pathogens on clinical management. Another important issue is the need for prophylaxis against spp. in immunocompromised patients.
LEARNING POINTS: In patients with vasculitis on systemic corticosteroid therapy or other immunosuppressive treatment, suspicion of uncommon infection should increase in parallel with the cumulative dose of these drugs.Obtaining an accurate diagnosis and early treatment is essential, but can be very challenging.Regular prophylactic therapy should be considered. However, more research is needed to determine whether higher doses of TMP/SMX would provide adequate coverage.

Keywords

References

  1. J Clin Microbiol. 2000 Jan;38(1):158-64 [PMID: 10618080]
  2. J Clin Microbiol. 2003 Feb;41(2):851-6 [PMID: 12574299]
  3. Acta Med Port. 2002 Nov-Dec;15(6):441-5 [PMID: 12680291]
  4. Acta Med Port. 2003 Mar-Apr;16(2):97-9 [PMID: 12828012]
  5. Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):61-4 [PMID: 15599783]
  6. Med J Aust. 1992 May 18;156(10):692-7 [PMID: 1620016]
  7. Respirology. 2007 May;12(3):394-400 [PMID: 17539844]
  8. Transpl Infect Dis. 2008 Feb;10(1):24-6 [PMID: 17651365]
  9. Infection. 2010 Apr;38(2):89-97 [PMID: 20306281]
  10. Med Mycol J. 2011;52(1):39-43 [PMID: 21441712]
  11. J Med Case Rep. 2011 Jun 23;5:228 [PMID: 21699674]
  12. Mayo Clin Proc. 2012 Apr;87(4):403-7 [PMID: 22469352]
  13. Singapore Med J. 2013 Jun;54(6):e127-30 [PMID: 23712786]
  14. Infect Dis Rep. 2014 Apr 04;6(1):5327 [PMID: 24757510]
  15. Antimicrob Agents Chemother. 2015 Jan;59(1):269-75 [PMID: 25348540]
  16. BMJ Case Rep. 2014 Nov 14;2014:null [PMID: 25398925]
  17. Lung India. 2016 Jul-Aug;33(4):398-403 [PMID: 27578932]
  18. Exp Ther Med. 2016 Oct;12(4):2021-2026 [PMID: 27698688]
  19. J Antimicrob Chemother. 2017 Mar 1;72(3):754-761 [PMID: 27999029]
  20. Rev Esp Quimioter. 2017 Apr;30(2):123-126 [PMID: 28176520]
  21. Microb Pathog. 2018 Jan;114:369-384 [PMID: 29146497]

Word Cloud

Created with Highcharts 10.0.0patientspresentcaseco-infectionrarepathogenstherapytreatmentImmunosuppressedgreaterriskunusualinfectionsauthorswomangiant-cellarteritisoralsteroidsdevelopedcavitatingpneumoniadueReportsliteraturehighlightsimportanceconsideringimmunosuppressednon-specificsymptomswellimpactclinicalmanagementAnotherimportantissueneedprophylaxissppimmunocompromisedLEARNINGPOINTS:vasculitissystemiccorticosteroidimmunosuppressivesuspicionuncommoninfectionincreaseparallelcumulativedosedrugsObtainingaccuratediagnosisearlyessentialcanchallengingRegularprophylacticconsideredHoweverresearchneededdeterminewhetherhigherdosesTMP/SMXprovideadequatecoverageCo-infectionPatientGiant-cellArteritisAspergillusImmunosuppressionNocardiacyriacigeorgica

Similar Articles

Cited By